Nephros (OTCMKTS:NEPH) was downgraded by ValuEngine from a “hold” rating to a “sell” rating in a research note issued to investors on Friday.

Shares of Nephros (NEPH) traded down $0.01 during trading on Friday, hitting $0.50. 26,259 shares of the company traded hands, compared to its average volume of 18,644. The company has a current ratio of 1.13, a quick ratio of 0.72 and a debt-to-equity ratio of 3.54. Nephros has a one year low of $0.18 and a one year high of $0.60.

Nephros (OTCMKTS:NEPH) last issued its quarterly earnings data on Thursday, November 9th. The company reported ($0.01) earnings per share for the quarter. Nephros had a negative return on equity of 358.70% and a negative net margin of 84.60%. The business had revenue of $0.92 million during the quarter. sell-side analysts predict that Nephros will post -0.05 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This story was first posted by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/12/02/valuengine-downgrades-nephros-neph-to-sell.html.

Nephros Company Profile

Nephros, Inc (Nephros) is a commercial-stage medical device and commercial products company that develops and sells high performance liquid purification filters and hemodiafiltration (HDF) systems. The Company’s filters, ultrafilters, are primarily used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate, and used in hospitals for the prevention of infection from water borne pathogens, such as legionella and pseudomonas.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Nephros Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nephros Inc. and related companies with MarketBeat.com's FREE daily email newsletter.